NAPLES, Italy, Sept. 6, 2023 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) today forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in affordable medicines, and the COPD Foundation, dedicated to enhancing the lives of COPD patients. This collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US..

意大利那不勒斯，2023年9月6日/PRNewswire/-全球制药主要羽扇豆有限公司（羽扇豆）今天与负担得起的药物先驱Mark Cumba Cost Plus Drug Company（Cost Plus Drugs）建立了独特的合作关系，COPD基金会致力于改善COPD患者的生活。这项合作旨在通过扩大美国COPD患者噻托溴铵吸入粉末18 mcg/胶囊的供应来加强获得医疗保健的机会。。

Lupin's Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Lupin的噻托溴铵吸入粉末，18 mcg/胶囊，是目前唯一可用于治疗相当于Spiriva®HandiHaler®（噻托溴铵吸入粉末），Boehringer Ingelheim Pharmaceuticals，Inc。的18 mcg/胶囊的通用产品。

Chronic obstructive pulmonary disease (COPD) affects over 15 million adults in the US and ranks as the fourth leading cause of death in the country. This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US.

慢性阻塞性肺病（COPD）影响美国超过1500万成年人，并成为该国第四大死因。这项合作标志着通过加强美国患者获得产品来应对疾病负担的重要里程碑。

Spiro Gavaris, President US Generics, Lupin, said, 'We believe there is a large unmet need for improved and affordable products for patients in the US. As a leading healthcare organization, we are committed to increasing access for patients, seeking treatment options for respiratory conditions like COPD, with our respiratory portfolio and pipeline.  Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reflects our intent to provide quality treatment options for patients.' .

Lupin美国仿制药总裁Spiro Gavaris说：“我们相信，美国患者需要改进和负担得起的产品，作为一家领先的医疗机构，我们致力于增加患者的使用机会，寻求治疗选择对于COPD等呼吸系统疾病，我们的呼吸组合和管道。我们与Mark Cumba Cost Plus制药公司和COPD基金会的合作反映了我们为患者提供优质治疗选择的意图 .

'We are excited to work with Lupin and the COPD Foundation to bring lower prescription drug prices to consumers,' said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. 'Cost Plus Drugs, Lupin and the COPD Foundation all share a common goal of providing consumers the lowest possible price for their prescription medication.

“我们很高兴与羽扇豆和COPD基金会合作，为消费者带来更低的处方药价格，”Mark Cumba Cost Plus制药公司首席执行官Alex Oshmyansky说成本加药物，羽扇豆和COPD基金会都有一个共同目标，即为消费者提供处方药的最低价格。

With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes.' .

通过成本加药品，消费者可以确信他们正在获得公平的价格和直接邮寄到家中的药物的便利性 .

'Accessible and affordable medications are a pathway to a healthier, more empowered life for COPD patients,' said Jean Wright, M.D., CEO of the COPD Foundation. 'Breathing freely shouldn't come at the cost of financial strain. Having a generic option will ensure that vital treatments remain within reach, allowing patients to prioritize their health.'.

COPD基金会首席执行官Jean Wright博士说：“获得和负担得起的药物是COPD患者获得更健康，更有权力的生活的途径。”自由呼吸不应该以经济压力为代价。有一个通用的选择将确保重要的治疗保持在可及的范围内，使患者能够优先考虑他们的健康。

About COPD Foundation

关于COPD基金会

The COPD Foundation is a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations to make treatment more effective and affordable. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure.

COPD基金会是一个非营利性组织，旨在通过扩大服务和加速创新以使治疗更有效和负担得起的举措，改善COPD，支气管扩张和非结核分枝杆菌（NTM）肺病患者的生活。基金会通过科学研究，教育，宣传和意识来预防疾病，缓慢进展并找到治疗方法。

For more information, visit copdfoundation.org, or follow us on Twitter and LinkedIn..

欲了解更多信息，请访问copdfoundation.org，或在Twitter和LinkedIn上关注我们。。

About Mark Cuban Cost Plus Drug Company

关于马克古巴成本加药品公司

The Mark Cuban Cost Plus Drug Company, PBC (www.costplusdrugs.com) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just `as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells.

马克古巴Cost Plus制药公司PBC（www.costplusdrugs.com）旨在从根本上改变制药业的运作方式。作为一家公益公司，其改善公共卫生的社会使命与底线同样重要。成本加药物透明地收取所销售的每种药物的标准加价。

The costplusdrugs.com online pharmacy launched in January 2022 now carries over 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide..

2022年1月推出的costplusdrugs.com在线药房现在拥有1000多种处方产品，每天通过邮件发送给数千名快乐客户。Cost Plus Drugs正在与健康计划，管理式护理组织，药房福利经理（PBM）和自保雇主合作，为全国雇主赞助的福利计划带来同样的储蓄。。

About Lupin Pharmaceuticals

关于羽扇豆制药

Lupin Pharmaceuticals, Inc. is the U.S. based wholly-owned subsidiary of Lupin Limited and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions. Together, all Lupin-owned entities combine to make up the 8th largest generic pharmaceutical company in the world by revenue size. Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals，Inc。是Lupin Limited的美国合资子公司，根据总处方量，是美国第三大制药公司。所有羽扇豆拥有的实体共同构成世界第八大仿制药公司的收入规模。羽扇豆制药公司。

is dedicated to delivering high-quality medications across many treatment areas. Lupin Pharmaceuticals Inc.'s branded pharmaceuticals division, is the provider of products designed to help prevent and manage women's health conditions with serious health consequences..

致力于在许多治疗领域提供高质量的药物。Lupin Pharmaceuticals Inc.的品牌药品部门是旨在帮助预防和管理女性健康状况并带来严重健康后果的产品提供商。。

© 2023 Lupin Pharmaceuticals, Inc. All rights reserved.

©2023 Lupin Pharmaceuticals，Inc。保留所有权利。

Spiriva® and HandiHaler® are registered trademarks of Boehringer Ingelheim Pharma GmbH & Co. KG

Spiriva® 和HandiHaler® 是Boehringer Ingelheim Pharma GmbH&Co.KG的注册商标

Logo: https://mma.prnewswire.com/media/1158525/lupin_pharmaceuticals_Logo.jpg

Logo: https://mma.prnewswire.com/media/1158525/lupin_pharmaceuticals_Logo.jpg

SOURCE Lupin Pharmaceuticals, Inc.

来源Lupin制药公司。